<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653675</url>
  </required_header>
  <id_info>
    <org_study_id>2741</org_study_id>
    <nct_id>NCT04653675</nct_id>
  </id_info>
  <brief_title>Cardiac Amyloidosis in Spinal Stenosis: the CASS-study</brief_title>
  <acronym>CASS</acronym>
  <official_title>Cardiac Amyloidosis in Spinal Stenosis: the CASS-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: A significant portion of cardiac amyloidosis patients have a 5 to 10 years prior&#xD;
      history of spinal canal stenosis, reflecting a diagnostic red flag that should raise&#xD;
      suspicion for amyloidosis presence. Mild troponin release and NT-proBNP elevation, both serum&#xD;
      cardiac biomarkers, often coincide with cardiac amyloidosis. Early cardiac amyloidosis&#xD;
      treatment improves survival, warranting timely diagnosis.&#xD;
&#xD;
      Study aim: to test a prospective screening strategy, based on serum cardiac biomarkers, to&#xD;
      increase early detection of cardiac amyloidosis in patients with spinal canal stenosis.&#xD;
&#xD;
      Design: Single-centre prospective observational non-interventional diagnostic study.&#xD;
&#xD;
      Methods: Consecutive patients during a one-year period in AZ Sint-Jan Bruges, without known&#xD;
      cardiac amyloidosis history and scheduled for spinal canal stenosis surgery, will have&#xD;
      cardiac evaluation including serum cardiac biomarker (high-sensitive troponin T and&#xD;
      NT-proBNP) assessment, electrocardiography and transthoracic echocardiography. During&#xD;
      surgery, all patients will undergo ligamentum flavum biopsy to evaluate presence and burden&#xD;
      of transthyretin amyloid deposition (Congo-red staining and immune histochemistry). All&#xD;
      patients with suspicion for cardiac amyloidosis will undergo further diagnostic testing&#xD;
      (including laboratory test and bone scintigraphy). A chronologic cascade screening process&#xD;
      will be used starting with abnormal serum cardiac biomarkers (high-sensitive troponin T ≥ 14&#xD;
      ng/ml and/or NT-proBNP &gt; 125 pg/ml), followed by electrocardiography, transthoracic&#xD;
      echocardiography and finally ligamentum flavum biopsy results. The diagnostic performance of&#xD;
      this biomarker-based strategy will be compared to electrocardiography, echocardiography and&#xD;
      ligamentum flavum biopsy.&#xD;
&#xD;
      Conclusion: It is hypothesised that serum cardiac biomarker testing in patients undergoing&#xD;
      spinal canal stenosis surgery represents a simple and valuable prospective screening strategy&#xD;
      for early detection of cardiac amyloid(osis).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance hs-Troponin T (ng/L) to early diagnose cardiac amyloidosis</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Diagnostic performance of a prospective screening strategy, based on elevated hs-Troponin T (ng/L), in patients with spinal canal stenosis undergoing spinal surgery, to early diagnose cardiac amyloidosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic performance of NT-proBNP (pg/ml) to early diagnose cardiac amyloidosis</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Diagnostic performance of a prospective screening strategy, based on elevated NT-proBNP (pg/ml), in patients with spinal canal stenosis undergoing spinal surgery, to early diagnose cardiac amyloidosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in diagnostic performance of NT-proBNP (pg/ml) and echocardiography, electrocardiography and ligamentum flavum biopsy</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of NT-proBNP (pg/ml) with CA suspicion based on echocardiography (left ventricular wall thickness), electrocardiography (QRS amplitude, presence of atrial fibrillation) and ligamentum flavum biopsy (presence of transthyretin-amyloid deposits)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in diagnostic performance of hs-Troponin T (ng/L) and electrocardiography parameters</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of hs-Troponin T (ng/L) with CA suspicion based on electrocardiography (QRS amplitude, presence of atrial fibrillation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diagnostic performance of hs-Troponin T (ng/L) and echocardiography parameters</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of hs-Troponin T (ng/L) with CA suspicion based on echocardiography (left ventricular wall thickness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diagnostic performance of hs-Troponin T (ng/L) and ligamentum flavum biopsy</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of hs-Troponin T (ng/L) with CA suspicion based on ligamentum flavum biopsy (presence of transthyretin-amyloid deposits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diagnostic performance of NT-proBNP (pg/ml) and echocardiography parameters</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of NT-proBNP (pg/ml) with CA suspicion based on echocardiography (left ventricular wall thickness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diagnostic performance of NT-proBNP (pg/ml) and electrocardiography parameters</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of NT-proBNP (pg/ml) with CA suspicion based on electrocardiography (QRS amplitude, presence of atrial fibrillation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diagnostic performance of NT-proBNP (pg/ml) and ligamentum flavum biopsy</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
    <description>Difference in diagnostic performance of NT-proBNP (pg/ml) with CA suspicion based on ligamentum flavum biopsy (presence of transthyretin-amyloid deposits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the prevalence of TTR amyloid in both cervical and lumbar spinal canal stenosis patients as function of age and clinical presentation</measure>
    <time_frame>6 months after spinal canal surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate TTR amyloid burden on ligamentum flavum biopsy to echocardiographic (e.g. ventricular wall thickness) parameters</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate TTR amyloid burden on ligamentum flavum biopsy to cardiac biomarker parameters (e.g. hs-Troponin T (ng/L))</measure>
    <time_frame>12 months after spinal canal surgery</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cervical or lumbar spinal canal stenosis scheduled for spinal surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cervical or lumbar spinal canal stenosis, scheduled for spinal surgery&#xD;
&#xD;
          -  &gt; 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prior diagnosis of cardiac amyloidosis and evident alternative explanations for troponin&#xD;
        and/or NT-proBNP elevation are the main reasons for exclusion.&#xD;
&#xD;
          -  known cardiac amyloidosis&#xD;
&#xD;
          -  severe valvular regurgitation or stenosis&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 40%&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≤ 25 ml/kg/min or dialysis&#xD;
&#xD;
          -  recent heart failure admission ≤ 1 month&#xD;
&#xD;
          -  recent myocarditis ≤ 3 months&#xD;
&#xD;
          -  recent acute coronary syndrome ≤ 1 month&#xD;
&#xD;
          -  recent percutaneous coronary intervention (PCI) ≤ 1 month&#xD;
&#xD;
          -  recent cardiac surgery ≤ 3 months&#xD;
&#xD;
          -  active or planned pregnancy&#xD;
&#xD;
          -  unwilling to participate or provide signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Debonnaire, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan AV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Debonnaire, MD, PhD</last_name>
    <phone>003250452670</phone>
    <email>philippe.debonnaire@azsintjan.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Lycke, MSc, PhD</last_name>
    <phone>003250453293</phone>
    <email>michelle.lycke@azsintjan.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Debonnaire</last_name>
      <phone>+3250452670</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Philippe Debonnaire</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

